Transaction DateRecipientSharesTypePriceValue
21st September 2020Venture Fund Xi, L.P. Atlas1,608,785Conversion of derivative$0.00
21st September 2020Venture Fund Xi, L.P. Atlas6,029,726Conversion of derivative$0.00
17th September 2020Venture Capital Vi, L.P. Versant8,000Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant1,187Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant8,000Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant79,216Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant1,187Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant6,901Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant1,177Other acquisition or disposition$0.00
17th September 2020Venture Capital Vi, L.P. Versant1,177Other acquisition or disposition$0.00
Akero Therapeutics
Akero Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.


Ticker: AKRO
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1744659
Employees: 13
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals